Skip to main content
. 2019 Jan 11;10:15. doi: 10.1186/s13287-018-1117-5

Table 2.

Baseline characteristics of treated limbs and transplants

Total, n = 103 Responders, n = 58 Non-responders, n = 45 P value
Rutherford class, n (%)
 IV 12 (11.6%) 5 (8.6%) 7 (15.6%) 0.277
 V 91 (88.4%) 53 (91.4%) 38 (84.4%) 0.277
Gangrene, n (%)
 Yes 46 (44.7%) 25 (43.1%) 21 (46.7%) 0.718
 No 57 (55.3%) 33 (56.9%) 24 (53.3%) 0.718
ABI* (median [IQR]) 0.485 (0.370–0.640) 0.515 (0.410–0.695) 0.430 (0.280–0.540) 0.011
TcPO2 (mmHg) (median [IQR]) 17 (6–28) 24 (14–30) 9 (4–19) < 0.001
Highest level of arterial occlusion
Above the knee or elbow, n (%) 62 (60.2%) 28 (46.6%) 34 (77.8%) 0.001
Common or external iliac artery, n (%) 4 (3.9%) 1 (1.7%) 3 (6.7%) 0.198
Common femoral artery or axillary artery, n (%) 5 (4.8%) 4 (6.9%) 1 (2.2%) 0.383
Superficial femoral artery or brachial artery, n (%) 36 (35.0%) 15 (25.9%) 21 (46.7%) 0.037
Popliteal artery, n (%) 17 (16.5%) 7 (12.1%) 10 (22.2%) 0.169
Below the knee or elbow, n (%) 41 (39.8%) 31 (53.4%) 10 (22.2%) 0.001
Artery in the calf or forearm, n (%) 28 (27.2%) 23 (39.7%) 5 (11.1%) 0.001
Artery below the ankle or wrist, n (%) 13 (12.6%) 8(13.7%) 5 (11.1%) 0.684
Type of transplantation
Purified for CD34+ cells, n (%) 52 (50.5%) 30 (51.7%) 22 (48.9%) 0.775
Not purified, n (%) 51 (49.5%) 28 (48.3%) 23 (51.1%) 0.775
Total transplanted CD34+ cells (million/L) (median [IQR]) 43.0 (26.0–84.0) 51.5 (26.0–103.0) 40.0 (26.0–68.0) 0.114
Cell viability (median [IQR]) 98.4% (97.7%–98.6%) 98.3% (97.5%–98.6%) 98.4% (98.2%–98.6%) 0.212

*ABIs of 99 patients with lower limbs treated were included in this analysis, while the other 4 patients with upper limbs treated were excluded

IQR, interquartile range; ABI, ankle-brachial index; TcPO2: transcutaneous pressure of oxygen; CD, cluster of differentiation